Vertex Pharmaceuticals Stock: Analyst Estimates & Ratings

Core Insights - Vertex Pharmaceuticals is a leading biopharmaceutical company focused on developing therapies for serious diseases, particularly known for its work in cystic fibrosis with drugs like Trikafta and Kalydeco [1] - The company's market capitalization is approximately $111.3 billion [1] Stock Performance - Over the past 52 weeks, Vertex's stock has decreased by 6.8%, while the S&P 500 Index has increased by 13.7% [2] - Year-to-date, Vertex's stock has risen by 7.8%, but this still lags behind the S&P 500's 13.4% gain [2] Sector Comparison - Vertex has underperformed compared to the Health Care Select Sector SPDR Fund, which has risen by 7% over the past 52 weeks and 10.3% year-to-date [3] Clinical and Regulatory Challenges - The decline in Vertex's stock is attributed to setbacks in its pain-drug pipeline, including a failed Phase 2 trial for VX-993 and regulatory hesitance from the FDA regarding its pain drug Journavx [4] - These issues have impacted investor confidence in Vertex's ability to diversify beyond its cystic fibrosis portfolio [4] Earnings Expectations - Analysts project Vertex's earnings per share (EPS) to grow to $15.99 for the fiscal year ending December 2025 [5] - The company's earnings surprise history is mixed, with three out of the last four quarters exceeding consensus estimates [5] Analyst Ratings - Among 34 analysts covering Vertex, the consensus rating is a "Moderate Buy," consisting of 19 "Strong Buy" ratings, one "Moderate Buy," 13 "Holds," and one "Strong Sell" [5] - This rating configuration has become slightly more bullish compared to two months ago, when there were 17 "Strong Buy" ratings [6]